Companies Dominating the Polycythemia Vera Treatment Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Galena Biopharma
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- PharmaEssentia Corporation
- Bayer AG
- Viatris Inc.
- Teva Pharmaceuticals Industries Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of thermosetting plastics is evaluated at USD 4.44 billion.
The polycythemia vera treatment market size was over USD 4.13 billion in 2024 and is poised to exceed USD 13.44 billion by 2037, witnessing over 9.5% CAGR during the forecast period i.e., between 2025-2037. The growing prevalence of polycythemia vera and increasing awareness about polycythemia vera treatment will drive the market growth.
North America industry is likely to dominate majority revenue share of 34% by 2037, due to high demand for novel drug delivery system along with development of advanced medication, and increasing investment in R&D activities in the region.
The major players in the market are Pfizer Inc.Galena BiopharmaBristol-Myers Squibb CompanyNovartis AGEli Lilly and CompanyPharmaEssentia CorporationBayer AGViatris Inc.Teva Pharmaceuticals Industries Ltd
